根据该协议的条款，该集团同意授予阿斯利康在全球开发、制造及商业化该化合物及该产品的独家授权。该集团将收取1.0亿美元的预付款，并有权收取最高3.7亿美元的潜在开发里程碑付款及最高15.5亿美元的潜在销售里程碑付款，以及根据该产品的年度销售净额计算的分层销售提成。CSPC Group (01093) opened more than 9% higher. As of press release, it rose 9.55% to HK$7.8, with a turnover of HK$0.114 billion.
The Zhitong Finance App learned that CSPC Group (01093) opened more than 9% higher. As of press release, it had risen 9.55% to HK$7.8, with a turnover of HK$0.114 billion.
According to the news, CSPC Group announced that it has entered into an exclusive licensing agreement with Astra Zeneca (AstraZeneca) to develop, manufacture and commercialize the group's lipoprotein (a) (Lipoprotein (a), Lp (a)) inhibitor YS2302018, and any drug or biological product composed of or containing this compound developed subsequently.
Under the terms of the agreement, the group agreed to grant AstraZeneca an exclusive license to develop, manufacture and commercialize the compound and product globally. The Group will receive an advance payment of 0.1 billion dollars and is entitled to receive potential development milestone payments of up to $0.37 billion and potential sales milestone payments of up to $1.55 billion, as well as tiered sales commissions calculated based on the product's annual net sales.
According to reports, as a leading preclinical drug candidate, the compound was discovered by the group's AI-driven small molecule drug design platform. The platform uses AI technology to analyze the binding pattern between target proteins and existing compound molecules, optimize their pharmacogenicity in a targeted manner, and finally screen out Lp (a) small molecule inhibitors with excellent developability. The compound shows effective binding to apolipoprotein (a) (Apolipoprotein (a), Apo (a)), thereby preventing it from assembling with ApoB-100 particles to form LP (a).
